# Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

> **NCT05027074** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 506 (actual)

## Conditions studied

- End-Stage Renal Disease
- End-Stage Kidney Disease
- Kidney Failure, Chronic

## Interventions

- **DRUG:** MK-2060
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05027074
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-17
- **Primary completion:** 2024-10-30
- **Final completion:** 2025-02-13
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027074, "Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05027074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*